Gilead Sciences

GILD Healthcare & Pharma 3/10 Low Risk
3/10
Sector avg: 2.8/10

Gilead Sciences carries $24.9B in long-term debt, with $24.9B in scheduled principal maturities. DebtCanary scores GILD at 3/10, suggesting manageable refinancing risk.

Maturity Schedule

Year 1 $2.8B Year 2 $0 Year 3 $0 Year 4 $0 Year 5 $0 Beyond 5 $22.1B
Period Amount Due % of Total
Year 1 (0-12 months) $2.8B 11.3%
Year 2 (12-24 months) N/A N/A
Year 3 (24-36 months) N/A N/A
Year 4 (36-48 months) N/A N/A
Year 5 (48-60 months) N/A N/A
Beyond 5 Years $22.1B 88.7%
Total Scheduled Maturities $24.9B 100.0%

Key Metrics

Total Long-Term Debt
$24.9B
Near-Term (12mo)
$2.8B
Interest Coverage
10.6x
Debt/Equity
1.10
Cash Coverage
1.93x
Operating Income
$10.0B

Score Components

Component Value Weight
Near-Term Maturity Concentration 11.3% 30%
Interest Coverage Ratio 10.6x 25%
Debt-to-Equity Ratio 1.10 25%
Cash Coverage of Near-Term Debt 1.93x 20%

Related Companies

Johnson & Johnson
JNJ
1/10
Debt: $41.4B 12mo: $2.0B
Pfizer
PFE
4/10
Debt: N/A 12mo: $3.0B
AbbVie
ABBV
4/10
Debt: $64.5B 12mo: $6.0B
Merck &
MRK
1/10
Debt: N/A 12mo: $2.6B
Eli Lilly
LLY
3/10
Debt: $29.5B 12mo: $781M
Bristol Myers Squibb
BMY
5/10
Debt: $44.8B 12mo: $2.0B
Amgen
AMGN
6/10
Debt: $54.6B 12mo: $4.6B
Regeneron Pharmaceuticals
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2025-12-31. Filing date: 2026-02-24. Data last fetched: 2026-03-29. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Complete.
View SEC EDGAR filings for Gilead Sciences →